Micafungin injection for the treatment of invasive candidiasis in pediatric patients under 4 months of age

References

• Clerihew L, Lamagni TL, Brocklehurst P, et al. Candida parapsilosis infection in very low birthweight infants. Arch Dis Childhood Fetal Neonatal Ed. 2007;92(2):F127–9. PubMed PMID: 17337658. Pubmed Central PMCID: PMC2675456. Epub 2007/03/06. eng.
   PubMed Web of Science ®Google Scholar
• Benjamin Jr DK, Ross K, McKinney Jr. RE Jr.Jr., et al. When to suspect fungal infection in neonates: a clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics. 2000;106(4):712–718. PubMed PMID: 11015513. Epub 2000/10/04. eng.
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr., Stoll BJ, Gantz MG, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics. 2010;126(4):e865–73. PubMed PMID: 20876174. Pubmed Central PMCID: PMC3045840. Epub 2010/09/30. eng.
   PubMed Web of Science ®Google Scholar
• Barton M, O’Brien K, Robinson JL, et al. Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls. BMC Infect Dis. 2014;14:327. PubMed PMID: 24924877. Pubmed Central PMCID: PMC4063435. Epub 2014/06/14. eng.
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr., Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117(1):84–92. PubMed PMID: 16396864. Epub 2006/01/07. eng.
   PubMed Web of Science ®Google Scholar
• Fisher BT, Ross RK, Localio AR, et al. Decreasing rates of invasive candidiasis in pediatric hospitals across the United States. Clin Infect Dis. 2014;58(1):74–77. PubMed PMID: 24114736. Epub 2013/10/12. eng.
   PubMed Web of Science ®Google Scholar
• Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother. 2005;56(Suppl 1):i5–i11. PubMed PMID: 16120635. Epub 2005/08/27. eng.
   PubMed Web of Science ®Google Scholar
• Cotten CM, McDonald S, Stoll B, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics. 2006;118(2):717–722. PubMed PMID: 16882828. Epub 2006/08/03. eng.
   PubMed Web of Science ®Google Scholar
• Lee JH, Hornik CP, Benjamin DK Jr., et al. Risk factors for invasive candidiasis in infants >1500 g birth weight. Pediatr Infect Dis J. 2013;32(3):222–226. PubMed PMID: 23042050. Pubmed Central PMCID: PMC3578110. Epub 2012/10/09. eng.
   PubMed Web of Science ®Google Scholar
• Caggiano G, Lovero G, De Giglio O, et al. Candidemia in the neonatal intensive care unit: a retrospective, observational survey and analysis of literature data. Biomed Res Int. 2017;2017:7901763. PubMed PMID: 28884129. Pubmed Central PMCID: PMC5572580. Epub 2017/09/09. eng.
   PubMed Web of Science ®Google Scholar
• Adams-Chapman I, Bann CM, Das A, et al. Neurodevelopmental outcome of extremely low birth weight infants with Candida infection. J Pediatr. 2013;163(4):961–7.e3. PubMed PMID: 23726546. Pubmed Central PMCID: PMC3786056. Epub 2013/06/04. eng.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Candidiasis. In: Kimberlin D, Barnett E, Lynfield R, et al., editors. Red book: 2021-2024 report of the committee of infectious diseases. 32nd ed. Itasca (IL): American Academy of Pediatrics; 2021. p. 246–252.
   Google Scholar
• Cohen-Wolkowiez M, Smith PB, Mangum B, et al. Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures. J Perinatol. 2007;27(2):97–100. PubMed PMID: 17080094. Epub 2006/11/03. eng.
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56(9):1284–1292. PubMed PMID: 23315320. Epub 2013/01/15. eng.
   PubMed Web of Science ®Google Scholar
• Cohen JF, Ouziel A, Matczak S, et al. Diagnostic accuracy of serum (1,3)-beta-d-glucan for neonatal invasive candidiasis: systematic review and meta-analysis. Clin Microbiol Infect. 2020;26(3):291–298. PubMed PMID: 31539634. Epub 2019/09/21. eng.
   PubMed Web of Science ®Google Scholar
• Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother. 2000;12(6):463–470. PubMed PMID: 11154026. Epub 2001/01/12. eng.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–50. PubMed PMID: 26679628. Pubmed Central PMCID: PMC4725385. Epub 2015/12/19. eng.
   PubMed Web of Science ®Google Scholar
• Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth-weight infants: therapeutic toxicity. Pediatrics. 1984;73(2):153–157. PubMed PMID: 6694870. Epub 1984/02/01. eng.
   PubMed Web of Science ®Google Scholar
• Loo AS, Muhsin SA, Walsh TJ. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. Expert Opin Drug Saf. 2013;12(6):881–895. PubMed PMID: 23931455. Epub 2013/08/13. eng.
   PubMed Web of Science ®Google Scholar
• Bes DF, Rosanova MT, Sberna N, et al. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting. Pediatr Infect Dis J. 2014;33(8):e198–206. PubMed PMID: 24618932. Epub 2014/03/13. eng.
   PubMed Web of Science ®Google Scholar
• Aghai ZH, Mudduluru M, Nakhla TA, et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol. 2006;26(9):550–555. PubMed PMID: 16940972. Epub 2006/08/31. eng.
   PubMed Web of Science ®Google Scholar
• Berkow EL, Lockhart SR. Fluconazole resistance in Candida species: a current perspective. Infect Drug Resist. 2017;10:237–245. PubMed PMID: 28814889. Pubmed Central PMCID: PMC5546770. Epub 2017/08/18. eng.
   PubMed Web of Science ®Google Scholar
• Wasmann RE, Muilwijk EW, Burger DM, et al. Clinical pharmacokinetics and pharmacodynamics of Micafungin. Clin Pharmacokinet. 2018;57(3):267–286. PubMed PMID: 28791666. Pubmed Central PMCID: PMC5814521 Catherijne A. Knibbe and David M. Burger declare that they have no conflicts of interest. Paul E. Verweij and Roger J. Brüggemann declare that they have served as consultants to and have received unrestricted research grants from Astellas Pharma Inc., F2G, Gilead Sciences, Merck Sharpe and Dohme Corp., and Pfizer Inc. All payments were invoiced by the Radboud University Medical Center. Epub 2017/08/10. eng.
   PubMed Web of Science ®Google Scholar
• Mochizuki K, Sawada A, Suemori S, et al. Intraocular penetration of intravenous micafungin in inflamed human eyes. Antimicrob Agents Chemother. 2013;57(8):4027–4030. PubMed PMID: 23689706. Pubmed Central PMCID: PMC3719741. Epub 2013/05/22. eng.
   PubMed Web of Science ®Google Scholar
• Okugawa S, Ota Y, Tatsuno K, et al. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. Scand J Infect Dis. 2007;39(4):344–346. PubMed PMID: 17454899. Epub 2007/04/25. eng.
   PubMed Web of Science ®Google Scholar
• Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54(8):1110–1122. PubMed PMID: 22412055. Epub 2012/03/14. eng.
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020–2029. PubMed PMID: 12490683. Epub 2002/12/20. eng.
   PubMed Web of Science ®Google Scholar
• Hashimoto S. Micafungin: a sulfated echinocandin. J Antibiot (Tokyo). 2009;62(1):27–35. PubMed PMID: 19132058. Epub 2009/01/10. eng.
   PubMed Web of Science ®Google Scholar
• Mycamine (micafungin sodium) injection [package insert]. Northbrook (IL) USA: Astellas Pharma US, Inc; 2020. [cited 2021 Aug 3]. Available from: https://www.astellas.us/docs/mycamine.pdf.
   Google Scholar
• Benjamin DK Jr., Kaufman DA, Hope WW, et al. A phase 3 study of micafungin versus Amphotericin B Deoxycholate in infants with invasive candidiasis. Pediatr Infect Dis J. 2018;37(10):992–998. PubMed PMID: 29596222. Pubmed Central PMCID: PMC6155365. Epub 2018/03/30. eng.
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. Drug Approval Package. Mycamine (micafungin sodium) injection; 2005. [cited 2021 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-506_Mycamine.cfm.
   Google Scholar
• European Medicines Agency. Human medicine European public assessment report (EPAR): mycamine. [cited 2021 Aug 3]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/mycamine.
   Google Scholar
• US Food & Drug Administration. Mycamine (micafungin sodium) injection; Revised 2008. [cited 2021 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021506s008lbl.pdf.
   Google Scholar
• US Food & Drug Administration. Mycamine (micafungin sodium) injection; Revised 2013. [cited 2021 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021506s015lbl.pdf
   Google Scholar
• Perlin DS. Current perspectives on echinocandin class drugs. Future Microbiol. 2011;6(4):441–457. PubMed PMID: 21526945. Pubmed Central PMCID: PMC3913534. Epub 2011/04/30. eng.
   PubMed Web of Science ®Google Scholar
• Messer SA, Diekema DJ, Boyken L, et al. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol. 2006;44(2):324–326. PubMed PMID: 16455878. Pubmed Central PMCID: PMC1392702. Epub 2006/02/04. eng.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Cota JM, Frei CR. Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. Infect Drug Resist. 2008;1:63–77. PubMed PMID: 21694882. Pubmed Central PMCID: PMC3108724. Epub 2008/01/01. eng.
   PubMedGoogle Scholar
• Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antifungal Susceptibilty for Yeasts. 2nd. Wayne (PA), USA: CLSI supplement M60; 2020. USA: https://clsi.org/media/3680/m60ed2_sample.pdf
   Google Scholar
• Emiroglu M. Micafungin use in children. Expert Rev Anti Infect Ther. 2011;9(9):821–834. PubMed PMID: 21905789. Epub 2011/09/13. eng.
   PubMed Web of Science ®Google Scholar
• Beauvais A, Bruneau JM, Mol PC, et al. Glucan synthase complex of Aspergillus fumigatus. J Bacteriol. 2001;183(7):2273–2279. PubMed PMID: 11244067. Pubmed Central PMCID: PMC95134. Epub 2001/03/13. eng.
   PubMed Web of Science ®Google Scholar
• Watabe E, Nakai T, Matsumoto S, et al. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother. 2003;47(6):1995–1998. PubMed PMID: 12760883. Pubmed Central PMCID: PMC155853. Epub 2003/05/23. eng.
   PubMed Web of Science ®Google Scholar
• Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother. 2002;46(9):3001–3012. PubMed PMID: 12183260. Pubmed Central PMCID: PMC127409. Epub 2002/08/17. eng.
   PubMed Web of Science ®Google Scholar
• Nakai T, Uno J, Otomo K, et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy. 2002;48(2):78–81. PubMed PMID: 12011539. Epub 2002/05/16. eng.
   PubMed Web of Science ®Google Scholar
• Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother. 2000;44(1):57–62. PubMed PMID: 10602723. Pubmed Central PMCID: PMC89628. Epub 1999/12/22. eng.
   PubMed Web of Science ®Google Scholar
• Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007;10(3):121–130. PubMed PMID: 17569573. Pubmed Central PMCID: PMC2696280. Epub 2007/06/16. eng.
   PubMed Web of Science ®Google Scholar
• Walker LA, Gow NA, Munro CA. Fungal echinocandin resistance. Fungal Genet Biol FG & B. 2010;47(2):117–126. PubMed PMID: 19770064. Pubmed Central PMCID: PMC2812698. Epub 2009/09/23. eng.
   PubMed Web of Science ®Google Scholar
• Perlin DS. Echinocandin Resistance in Candida. Clin Infect Dis. 2015;61(Suppl 6):S612–7. PubMed PMID: 26567278. Pubmed Central PMCID: PMC4643482. Epub 2015/11/15. eng.
   PubMed Web of Science ®Google Scholar
• Patil A, Majumdar S. Echinocandins in antifungal pharmacotherapy. J Pharm Pharmacol. 2017;69(12):1635–1660. PubMed PMID: 28744860. Epub 2017/07/27. eng.
   PubMed Web of Science ®Google Scholar
• Groll AH, Mickiene D, Petraitis V, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother. 2001;45(12):3322–3327. PubMed PMID: 11709303. Pubmed Central PMCID: PMC90832. Epub 2001/11/16. eng.
   PubMed Web of Science ®Google Scholar
• Yamada N, Kumada K, Kishino S, et al. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J Infect Chemother. 2011;17(5):731–734. PubMed PMID: 21537970. Epub 2011/05/04. eng.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Lewis JS 2nd. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007;8(8):1155–1166. PubMed PMID: 17516879. Epub 2007/05/23. eng.
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet (London Engl). 2003;362(9390):1142–1151. PubMed PMID: 14550704. Epub 2003/10/11. eng.
   PubMed Web of Science ®Google Scholar
• Fromtling RA. Micafungin sodium (FK-463). Drugs Today (Barc). 2002;38(4):245–257. PubMed PMID: 12532193. Epub 2003/01/18. eng.
   PubMed Web of Science ®Google Scholar
• Hirata K, Aoyama T, Matsumoto Y, et al. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi. 2007;127(5):897–901. PubMed PMID: 17473532. Epub 2007/05/03. eng.
   PubMed Web of Science ®Google Scholar
• Maseda E, Grau S, Villagran MJ, et al. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration. J Antimicrob Chemother. 2014;69(6):1624–1632. PubMed PMID: 24505092. Epub 2014/02/08. eng.
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis. 2006;42(8):1171–1178. PubMed PMID: 16575738. Epub 2006/04/01. eng.
   PubMed Web of Science ®Google Scholar
• Yanni SB, Smith PB, Benjamin DK Jr., et al. Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. Biopharm Drug Dispos. 2011;32(4):222–232. PubMed PMID: 21449041. Pubmed Central PMCID: PMC3080470. Epub 2011/03/31. eng.
   PubMed Web of Science ®Google Scholar
• Kawada M, Fukuoka N, Kondo M, et al. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. Pediatr Infect Dis J. 2009;28(9):840–842. PubMed PMID: 19636279. Epub 2009/07/29. eng.
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr., Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010;87(1):93–99. PubMed PMID: 19890251. Pubmed Central PMCID: PMC2824925. Epub 2009/11/06. eng.
   PubMed Web of Science ®Google Scholar
• Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25(12):1110–1115. PubMed PMID: 17133155. Epub 2006/11/30. eng.
   PubMed Web of Science ®Google Scholar
• Ikeda F, Wakai Y, Matsumoto S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother. 2000;44(3):614–618. PubMed PMID: 10681327. Pubmed Central PMCID: PMC89735. Epub 2000/02/19. eng.
   PubMed Web of Science ®Google Scholar
• Warn PA, Sharp A, Morrissey G, et al. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother. 2002;50(6):1071–1074. PubMed PMID: 12461036. Epub 2002/12/04. eng.
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2002;46(6):1857–1869. PubMed PMID: 12019101. Pubmed Central PMCID: PMC127233. Epub 2002/05/23. eng.
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Hope WW, et al. Cerebrospinal fluid and plasma (1–>3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis. Antimicrob Agents Chemother. 2008;52(11):4121–4129. PubMed PMID: 18779361. Pubmed Central PMCID: PMC2573149. Epub 2008/09/10. eng.
   PubMed Web of Science ®Google Scholar
• Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008;197(1):163–171. PubMed PMID: 18171300. Pubmed Central PMCID: PMC2732769. Epub 2008/01/04. eng.
   PubMed Web of Science ®Google Scholar
• NDA multi-disciplinary review and evaluation NDA 21506/S-023: mycamine (micafungin sodium); 2019. [cited 2021 Aug 3]. Available from: https://www.fda.gov/media/134936/download
   Google Scholar
• Taormina G, Gopinath R, Moore J, et al. A regulatory review approach for evaluation of Micafungin for treatment of neonatal candidiasis. Clin Infect Dis. 2021. PubMed PMID: 33458754. Epub 2021/01/19. eng. DOI:https://doi.org/10.1093/cid/ciab025.
   Google Scholar
• Tezer H, Canpolat FE, Dilmen U. Invasive fungal infections during the neonatal period: diagnosis, treatment and prophylaxis. Expert Opin Pharmacother. 2012;13(2):193–205. PubMed PMID: 22220691. Epub 2012/01/10. eng.
   PubMed Web of Science ®Google Scholar
• Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49(8):3317–3324. PubMed PMID: 16048942. Pubmed Central PMCID: PMC1196271. Epub 2005/07/29. eng.
   PubMed Web of Science ®Google Scholar
• Leroux S, Jacqz-Aigrain E, Elie V, et al. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial. Br J Clin Pharmacol. 2018;84(9):1989–1999. PubMed PMID: 29744900. Pubmed Central PMCID: PMC6089805. Epub 2018/05/11. eng.
   PubMed Web of Science ®Google Scholar
• Testoni D, Smith PB, Benjamin DK Jr. The use of antifungal therapy in neonatal intensive care. Clin Perinatol. 2012;39(1):83–98. PubMed PMID: 22341539. Pubmed Central PMCID: PMC3285432. Epub 2012/02/22. eng.
   PubMed Web of Science ®Google Scholar
• Bersani I, Piersigilli F, Goffredo BM, et al. Antifungal drugs for invasive Candida infections (ICI) in neonates: future perspectives. Front Pediatr. 2019;7:375. PubMed PMID: 31616647. Pubmed Central PMCID: PMC6764087. Epub 2019/10/17. eng.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Mycamine (micafungin sodium) product information; 2020. [cited 2021 Aug 3]. Available from: https://www.ema.europa.eu/en/documents/product-information/mycamine-epar-product-information_en.pdf
   Google Scholar
• Manzoni P, Wu C, Tweddle L, et al. Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials. Pediatr Infect Dis J. 2014;33(11):e291–8. PubMed PMID: 24892849. Pubmed Central PMCID: PMC4196786. Epub 2014/06/04. eng.
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27(9):820–826. PubMed PMID: 18679151. Epub 2008/08/06. eng.
   PubMed Web of Science ®Google Scholar
• Auriti C, Falcone M, Ronchetti MP, et al. High-dose Micafungin for preterm neonates and infants with invasive and central nervous system candidiasis. Antimicrob Agents Chemother. 2016;60(12):7333–7339. PubMed PMID: 27697761. Pubmed Central PMCID: PMC5119014. Epub 2016/10/05. eng.
   PubMed Web of Science ®Google Scholar
• Auriti C, Goffredo BM, Ronchetti MP, et al. High-Dose Micafungin in neonates and young infants with invasive candidiasis: results of a phase 2 study. Antimicrob Agents Chemother. 2021;65(4). PubMed PMID: 33558294. Pubmed Central PMCID: PMC8097467. Epub 2021/02/10. eng. DOI:https://doi.org/10.1128/AAC.02494-20.
   Google Scholar
• Aliaga S, Clark RH, Laughon M, et al. Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics. 2014;133(2):236–242. PubMed PMID: 24446441. Pubmed Central PMCID: PMC3904270. Epub 2014/01/22. eng.
   PubMed Web of Science ®Google Scholar
• Healy CM, Campbell JR, Zaccaria E, et al. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics. 2008;121(4):703–710. PubMed PMID: 18381534. Epub 2008/04/03. eng.
   PubMed Web of Science ®Google Scholar
• Maede Y, Ibara S, Nagasaki H, et al. Micafungin versus fluconazole for prophylaxis against fungal infections in premature infants. Pediatr Int off J Japan Pediatr Soc. 2013;55(6):727–730. PubMed PMID: 23773357. Epub 2013/06/19. eng.;():.
   PubMed Web of Science ®Google Scholar
• Takaki K, Shimono N, Ishimaru T, et al. Detection of Candida antigen and antibody from patients with invasive candidiasis. Int J Infect Dis. 1996;1:78–82.
   Google Scholar
• European Medicines Agency. Mycamine EPAR; 2018. [cited 2021 Oct 30]. Available from: https://www.ema.europa.eu/en/documents/product-information/mycamine-epar-product-information_en.pdf
   Google Scholar
• de La Torre P, Reboli AC. Micafungin: an evidence-based review of its place in therapy. Core Evid. 2014;9:27–39. PubMed PMID: 24596542. Pubmed Central PMCID: PMC3940642. Epub 2014/03/07. eng.
   PubMedGoogle Scholar
• European Committee on Antimicrobial Susceptibilty testing. Breakpoint tables for interpretation of MICs for antifungal agents. Basel; 2020. [cited 2021 Aug 3]. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Clinical_breakpoints/AFST_BP_v10.0_200204_updatd_links_200924.pdf
   Google Scholar
• Spreghini E, Orlando F, Sanguinetti M, et al. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata. Antimicrob Agents Chemother. 2012;56(3):1215–1222. PubMed PMID: 22203604. Pubmed Central PMCID: PMC3294882. Epub 2011/12/29. eng.
   PubMed Web of Science ®Google Scholar
• Ernst EJ, Roling EE, Petzold CR, et al. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother. 2002;46(12):3846–3853. PubMed PMID: 12435687. Pubmed Central PMCID: PMC132786. Epub 2002/11/19. eng.
   PubMed Web of Science ®Google Scholar